Whats the prevalence of KRAS and BRAF comutation in metastatic colon cancer
Best insight from top research papers
The prevalence of KRAS and BRAF comutation in metastatic colon cancer varies across different studies. A study in Iranian metastatic colorectal cancer (mCRC) patients found that KRAS mutations were present in 33.6% of cases, with no BRAF mutations detected . Another global review reported a median global prevalence of KRAS mutations in CRC patients at 38%, with the KRAS G12C mutation specifically at 3.1% . Additionally, a study in South India found KRAS mutations in 18.75% of metastatic colorectal cancer cases analyzed . These findings highlight the variability in KRAS mutation rates in metastatic colon cancer, with BRAF mutations being less common or absent in some populations.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| Not addressed in the paper. | |
2 Citations | Not addressed in the paper. |
23 Citations | KRAS mutations were found in 33.6% of metastatic colorectal cancer cases in Iran, while no BRAF mutations were detected, indicating a lack of comutation between KRAS and BRAF. |
| Not addressed in the paper. | |
| Not addressed in the paper. |
Related Questions
What is the percentage of patients moving to 2L and 3L in KRAS G12 mutated colorectal cancer?5 answersIn colorectal cancer (CRC) patients with KRAS G12 mutations, approximately 47% move to the second line (2L) of treatment, and around 35% progress to the third line (3L) of treatment. The prevalence of the KRAS G12C mutation in CRC is around 3.1%, with limited evidence suggesting a lower objective response rate and inferior disease-free/relapse-free survival in these patients compared to those with other KRAS mutations. Additionally, KRAS G12D mutation is relatively common in CRC, accounting for 30.8% of all KRAS mutations in CRC cases. The KRAS G12D mutation is associated with unique clinical and genomic characteristics, and it co-occurs with PIK3CA mutation in CRC cases.
What is the current understanding of the epidemiology of KRAS G12C-mutated colorectal cancer (CRC)??5 answersThe epidemiology of KRAS G12C-mutated colorectal cancer (CRC) is significant due to its association with poor prognosis and resistance to EGFR targeted therapy. KRAS mutations, including G12C, are prevalent in CRC, with approximately 30% of all cancer cases and nearly 50% of metastatic CRC cases exhibiting KRAS mutations. Recent advancements have led to the development of allele-specific covalent inhibitors targeting KRAS G12C, such as Sotorasib and Adagrasib, which have shown promising efficacy in CRC treatment. The location of KRAS mutations, such as G12C, can impact survival outcomes in CRC patients, with specific mutation locations like G12S correlating with shorter overall survival times. Understanding the prevalence and implications of KRAS G12C mutations in CRC is crucial for guiding targeted treatment strategies and improving patient outcomes.
What is the current understanding of the epidemiology of KRAS G12C-mutated CRC?5 answersThe global prevalence of KRAS mutations in colorectal cancer (CRC) is estimated at 38%, with the KRAS G12C mutation specifically found in 3.1% of patients with CRC, indicating its significance in the disease. Studies have shown that KRAS G12C mutations are more common in right-sided colon tumors and are associated with a lower objective response rate and inferior disease-free survival compared to other KRAS mutations. Furthermore, research in the Argentine population revealed a prevalence of 14.48% for KRAS G12C mutations, with significant associations observed between this mutation and advanced cancer stages and smoking history. In pancreatic cancer, colorectal cancer, and non-small-cell lung cancer, the prevalence of KRAS G12C mutations varies, with unique clinical and genomic characteristics identified in each cancer type. Additionally, in advanced PDAC patients with KRAS G12C mutations, treatment with gemcitabine and nab-paclitaxel (GP) showed significantly longer median overall survival compared to FOLFIRINOX.
What are the current epidemiological trends in the incidence and prevalence of metastatic melanoma globally?5 answersMetastatic melanoma, a significant public health concern, exhibits varying epidemiological trends globally. The incidence of melanoma is on the rise, particularly in fair-skinned populations with excessive sun exposure. Mortality rates have been increasing in most regions, albeit at a slower pace than incidence, with a notable drop in the United States due to new treatments for stage 4 melanoma. Targeted therapies like BRAF/MEK inhibitors and immunotherapies have contributed to improved survival rates, especially in the US where mortality has decreased by almost 30% over the past decade. Despite advancements, challenges like resistance to treatments and limited efficacy in some patients persist, emphasizing the need for better biomarkers to enhance treatment selection and outcomes. These trends underscore the importance of continued research and interventions to address the evolving landscape of metastatic melanoma globally.
What is the prevalence of KRAS mutations in urothelial cancer?5 answersThe prevalence of KRAS mutations in urothelial cancer varies depending on the study. One study found that the frequency of RAS mutations, including KRAS, in bladder cancer patients was 11.2%. Another study focused specifically on urothelial carcinomas and found that KRAS mutations accounted for 28.6% of RAS mutations in bladder cancer patients. However, it is important to note that these studies had different sample sizes and methodologies, so the exact prevalence may vary.
What is importance of braf mutations in colon cancer?5 answersBRAF mutations in colon cancer are of significant importance. Patients with BRAF mutated colon cancer have poor survival outcomes and controversial treatment strategies. The tumor microenvironment in BRAF mutated colon cancer is different, with more stromal cells, immune cell infiltration, and lower tumor purity. Several immunotherapeutic targets, such as PD-1, PD-L1, CTLA-4, LAG-3, and TIM-3, are highly expressed in BRAF mutated patients. BRAF mutation is also associated with higher proportions of neutrophils and macrophages M1, and lower proportions of plasma cells, dendritic cells resting, and T cells CD4 naive. BRAF mutations are observed at high frequency in right-side colon cancer, especially in the cecum, and can be detected in plasma. BRAF mutations in colorectal cancer stratified for molecular background have prognostic and clinical significance. In stage IV CRC, BRAF mutations are an independent negative prognostic factor, but patients with BRAF mutations may have better prognoses if treated with chemotherapy prior to tumor resection.